Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages

Auteurs

C.A. Gomez-Roca, A. Italiano, C. Le Tourneau, P.A. Cassier, M. Toulmonde, S.P. D’Angelo, M. Campone, K.L. Weber, D. Loirat, M.A. Cannarile, A.-M. Jegg, C. Ries, R. Christen, G. Meneses-Lorente, W. Jacob, I. Klaman, C.-H. Ooi, C. Watson, K. Wonde, B. Reis, F. Michielin, D. Rüttinger, J.-P. Delord, J.-Y. Blay